- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07450547
Fase 2-studie om de veiligheid en werkzaamheid van ANG003 te beoordelen
Een fase 2, multicenter, gerandomiseerd, actief gecontroleerd onderzoek naar de veiligheid en werkzaamheid van ANG003 bij twee verschillende doseringsniveaus bij proefpersonen met exocriene pancreasinsufficiëntie ten gevolge van cystische fibrose
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Evan Bailey, MD
- Telefoonnummer: 617-466-3111
- E-mail: medical@anagramtx.com
Studie Locaties
-
-
California
-
Long Beach, California, Verenigde Staten, 90806
- Werving
- Long Beach Memorial Medical Center
-
Contact:
- Angelica Rodriguez
- Telefoonnummer: 562-706-1245
- E-mail: ARodriguez9@memorialcare.org
-
Los Angeles, California, Verenigde Staten, 90033
- Werving
- Center for Cystic Fibrosis at Keck Medical Center of USC
-
Contact:
- Lynn Fukushima
- Telefoonnummer: 323-442-8522
- E-mail: lynn.fukushima@med.usc.edu
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80206
- Werving
- National Jewish Health
-
Contact:
- Alix Wilson
- Telefoonnummer: 303-270-2517
- E-mail: wilsona@njhealth.org
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32610
- Nog niet aan het werven
- University of Florida
-
Contact:
- Alexa Smith
- Telefoonnummer: 352-273-8380
- E-mail: alexa.howell@ufl.edu
-
Orlando, Florida, Verenigde Staten, 32803
- Nog niet aan het werven
- Central Florida Pulmonary Group
-
Contact:
- Desiree Serr
- Telefoonnummer: 407-303-7192
- E-mail: desiree.serr1@adventhealth.com
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30324
- Werving
- Emory-Children's Healthcare of Atlanta Cystic Fibrosis Center
-
Contact:
- Eric Hunter
- Telefoonnummer: 678-977-5212
- E-mail: eahunte@emory.edu
-
-
Illinois
-
Glenview, Illinois, Verenigde Staten, 60025
- Werving
- The Cystic Fibrosis Institute
-
Contact:
- Steven R Boas, MD
- Telefoonnummer: 847-998-3434
- E-mail: sboas@wecare4lungs.com
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- Nog niet aan het werven
- University of Iowa
-
Contact:
- Mary Teresi
- Telefoonnummer: 319-384-7546
- E-mail: mary-teresi@uiowa.edu
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66160
- Werving
- University of Kansas Medical Center
-
Contact:
- Lawrence Scott
- Telefoonnummer: 913-588-4020
- E-mail: lscott2@kumc.edu
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40506
- Werving
- University of Kentucky
-
Contact:
- Chase Whitaker
- Telefoonnummer: 859-218-4810
- E-mail: chase.whitaker@uky.edu
-
-
Maine
-
Portland, Maine, Verenigde Staten, 04102
- Nog niet aan het werven
- MaineHealth Pediatric Specialty Care
-
Contact:
- Rebecca Edwards
- Telefoonnummer: 207-662-6712
- E-mail: rebecca.edwards@mainehealth.org
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Werving
- Massachusetts General Hospital
-
Contact:
- Margot Hardcastle
- Telefoonnummer: 617-726-3719
- E-mail: mhardcastle@mgh.harvard.edu
-
Boston, Massachusetts, Verenigde Staten, 02115
- Werving
- Boston Children's Hospita
-
Contact:
- Robert Fowler
- Telefoonnummer: 617-355-1834
- E-mail: Robert.fowler@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- Werving
- University of Michigan, Michigan Medicine
-
Contact:
- Dawn Kruse
- Telefoonnummer: 734-615-3266
- E-mail: dmkruse@med.umich.edu
-
Detroit, Michigan, Verenigde Staten, 48201
- Werving
- Wayne State University Harper University Hospital
-
Contact:
- Debra Driscoll
- Telefoonnummer: 313-745-2221
- E-mail: ddriscol@med.wayne.edu
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55455
- Werving
- University of Minnesota
-
Contact:
- Brooke Noren, RN, BSN, CCRC
- Telefoonnummer: 612-625-7995
- E-mail: boer0039@umn.edu
-
-
New Jersey
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Werving
- Rutgers - Robert Wood Johnson Medical School
-
Contact:
- Sheila Redding
- Telefoonnummer: 732-235-7840
- E-mail: sr1238@rwjms.rutgers.edu
-
-
New York
-
Valhalla, New York, Verenigde Staten, 10595
- Nog niet aan het werven
- New York Medical College at Westchester Medical Center
-
Contact:
- Zachary Messer
- Telefoonnummer: 914-594-2352
- E-mail: Zachary_Messer@nymc.edu
-
-
Ohio
-
Akron, Ohio, Verenigde Staten, 44308
- Werving
- Children's Hospital Medical Center of Akron
-
Contact:
- Michelle Parrish
- Telefoonnummer: 330-543-3089
- E-mail: MParrish@akronchildrens.org
-
Cleveland, Ohio, Verenigde Staten, 44106
- Werving
- Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
-
Contact:
- Primary RC & Participant Contact General Contact
- Telefoonnummer: 216-844-3911
- E-mail: RainbowCFResearch@UHhospitals.org
-
Columbus, Ohio, Verenigde Staten, 43205
- Werving
- Nationwide Children's Hospital, Columbus
-
Contact:
- Diana Gilmore
- Telefoonnummer: 614-722-4752
- E-mail: diana.gilmore@nationwidechildrens.org
-
Toledo, Ohio, Verenigde Staten, 43606
- Werving
- Toledo Children's Hospital
-
Contact:
- Kelly Hoot
- Telefoonnummer: 419-291-4630
- E-mail: kelly.hoot@promedica.org
-
-
Pennsylvania
-
Hershey, Pennsylvania, Verenigde Staten, 17033
- Werving
- Hershey Medical Center Pennsylvania State University
-
Contact:
- Diane Kitch
- Telefoonnummer: 717-531-5646
- E-mail: dkitch@pennstatehealth.psu.edu
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15224
- Nog niet aan het werven
- University of Pittsburgh Medical Center
-
Contact:
- Adrienne DeRicco
- Telefoonnummer: 412-692-8069
- E-mail: adrienne.dericco2@upmc.edu
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75207
- Werving
- University of Texas Southwestern / Children's Health
-
Contact:
- Keianna Brown
- Telefoonnummer: 214-456-5489
- E-mail: Keianna.brown@utsouthwestern.edu
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112
- Werving
- Adult Cystic Fibrosis Center at the University of Utah
-
Contact:
- Kristyn Packer
- Telefoonnummer: 801-520-5106
- E-mail: kristyn.packer@hsc.utah.edu
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53792
- Werving
- University of Wisconsin
-
Contact:
- Melanie Nelson
- Telefoonnummer: 608-265-4617
- E-mail: mnelson@pediatrics.wisc.edu
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Nog niet aan het werven
- Froedtert & Medical College of Wisconsin
-
Contact:
- Erin Hubertz
- Telefoonnummer: 414-955-7019
- E-mail: ehubertz@mcw.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Male and female subjects aged ≥12 years from the date of informed consent in the US and aged ≥18 years in the EU
-
Confirmed and documented diagnosis of CF
-
Diagnosed with severe EPI as defined by a fecal elastase ≤50 μg/g stool measured at Screening by a central laboratory.
-
Subject has controlled EPI and taking a stable dose of pancreatic enzyme replacement therapy (PERT) for 90 days prior to Screening.
-
Adequate nutritional status measured by body mass index (BMI) defined by:
- BMI ≥25th percentile for children aged 12-17 years
- BMI ≥18.5 kg/m2 for ≥18 years of age
Exclusion Criteria:
- History of fibrosing colonopathy or recurring distal intestinal obstructive syndrome within 6 months of Screening.
- History of lung or liver transplant, listing for organ transplant or significant bowel resection within the last 6 months. Subjects with a history of resection that does not result in short bowel syndrome are eligible.
- Known hypersensitivity or other severe reaction to any ingredient of the investigational product (IP), Creon, or the stool marker (FD&C Blue #2).
- Any chronic diarrheal illness unrelated to pancreatic insufficiency, actively being treated for small intestinal bacterial overgrowth, requiring use of naso-gastric, J-tube, G-tube, and/or enteral feeding for the study duration, Clostridioides difficile infection within 6 months prior to Screening, or severe constipation defined as <1 bowel movement/week.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: ANG003 Dose A
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose A for a 21-day acclimation and subsequent CFA analysis. |
160,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
|
Experimenteel: ANG003 Dose B
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose B for a 21-day acclimation and subsequent CFA analysis. |
240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
|
Actieve vergelijker: Creon
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to Creon for an additional 21-days and subsequent CFA analysis. |
The commercially available pPERT Creon will be the active comparator in the study. Subjects will be instructed to take Creon according to the package insert and PI direction. |
|
Geen tussenkomst: Off Enzyme
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to the off enzyme arm. Subjects will receive Creon for an additional 21-day and the subsequent CFA analysis will be off enzyme. Total time off enzyme will be 4-7 days. |
|
|
Ander: 60% to <80% CFA ANG003 Dose B
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. Participants with a Period A CFA result of 60% to <80% will be assigned to ANG003 Dose B. |
240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values
Tijdsspanne: From Visit 1 to Visit 5, anticipated average 80 days
|
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values |
From Visit 1 to Visit 5, anticipated average 80 days
|
|
Coefficient of Fat Absorption (CFA)
Tijdsspanne: Period A (baseline) and Period B 72 hour CFA collection
|
Mean change from baseline CFA (i.e., Period B CFA minus Period A CFA) assessed for ANG003 Dose A, ANG003 Dose B, and Creon amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour CFA collection
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Plasma docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (ug/mL)
Tijdsspanne: Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
|
|
Coefficient of Nitrogen Absorption (CNA)
Tijdsspanne: Period A (baseline) and Period B 72 hour CNA collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour CNA collection
|
|
% of subjects with GI symptoms
Tijdsspanne: From Visit 2 to Visit 5, anticipated average 59 days
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
From Visit 2 to Visit 5, anticipated average 59 days
|
|
Cumulative stool weight
Tijdsspanne: Period A (baseline) and Period B 72 hour collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour collection
|
|
Number of Stools per Day
Tijdsspanne: Period A (baseline) and Period B 72 hour collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour collection
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Correlation between DHA/EPA and CFA
Tijdsspanne: Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
|
Mean change from baseline for each treatment group with a baseline CFA ≥80% |
Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
|
|
Coefficient of Fat Absorption (CFA) for subjects with a baseline CFA of 60% to <80% (analyzed separately)
Tijdsspanne: Period A (baseline) and Period B 72 hour CFA collection
|
Mean change from baseline for each treatment group with a baseline CFA 60% to <80% |
Period A (baseline) and Period B 72 hour CFA collection
|
|
Mean Period B CFA for all subjects randomized to the Off Enzyme arm with a baseline CFA ≥80%
Tijdsspanne: Period B 72 hour CFA collection
|
Period B CFA Off Enzyme in subjects with a baseline CFA ≥80% |
Period B 72 hour CFA collection
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Genetische ziekten, aangeboren
- Ziekten van de luchtwegen
- Ziekten van het spijsverteringsstelsel
- Longziekten
- Baby, pasgeborene, ziekten
- Alvleesklier Ziekten
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Taaislijmziekte
- Exocriene pancreasinsufficiëntie
- Hydrolasen
- Enzymen
- Enzymen en co -enzymen
- Complexe mengsels
- Lipase
- Carbonylische esterhydrolasen
- Esterasen
- Pancreasuittreksels
- Weefsel -extracten
- Pancrelipase
Andere studie-ID-nummers
- ANG003-25-201
- 2025-524569-25-00 (Ctis)
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .